DARVON N COMPOUND PULVULE 405 DIN 00261459
Health Canada record
| Active ingredient(s) | DEXTROPROPOXYPHENE NAPSYLATE 100 MG; ACETYLSALICYLIC ACID 375 MG; CAFFEINE 30 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | NARCOTICS (CDSA I) |
| Class | Human |
| ATC | N02AC54 DEXTROPROPOXYPHENE, COMB EXCL PSYCHOLEPT |
| Original market date | 31-Dec-1973 |
| Current status date | 11-Aug-1999 |
| Source | Health Canada DPD |
Establishment licence of the holder
Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEXTROPROPOXYPHENE NAPSYLATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00261432 | DARVON-N | PALADIN PHARMA INC. | Capsule | DEXTROPROPOXYPHENE NAPSYLATE 100 MG | Cancelled Post Market |
International API supply for DEXTROPROPOXYPHENE NAPSYLATE
0 active FDA Drug Master Files.
Request a quote for DARVON N COMPOUND PULVULE 405